Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Tecentriq (atezolizumab) / Roche

CCGLC-009, NCT06194695: DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma

Recruiting

N/A

100

RoW

drug eluting beads-transcatheter arterial chemoembolization, DEB-TACE, envatinib plus anti-PD(L)1

Ze-yang Ding, MD, Geneplus-Beijing Co. Ltd., Chinese Cooperative Group of Liver Cancer (CCGLC)

Cholangiocarcinoma Non-resectable

12/24

06/25

NCT03850028 / 2017-003511-20: Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients

Withdrawn

N/A

Europe

89Zr-atezolizumab PET scans

University Medical Center Groningen, Amsterdam UMC, location VUmc, Stichting Hemato-Oncologie voor Volwassenen Nederland, Hoffmann-La Roche

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

05/22

NCT04862949: Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

Completed

N/A

124

RoW

Atezolizumab plus bevacizumab

CHA University, Hoffmann-La Roche

Advanced Hepatocellular Carcinoma

12/22

03/23

NCT04869501: Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer

No Longer Available

N/A

TJ004309, Atezolizumab, Tecentriq

I-Mab Biopharma US Limited

Cancer

J-TAIL-2, NCT04501497: Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer

Completed

N/A

1221

Japan

Chugai Pharmaceutical, Japan Lung Cancer Society

Non-small Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer

02/23

NCT03559647: The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy

Completed

N/A

358

Europe

Atezolizumab

Hoffmann-La Roche

Non-Small Cell Lung Cancer (NSCLC)

08/23

NCT05173298: Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Recruiting

N/A

100

RoW

atezolizumab plus bevacizumab

CHA University, Boryung Pharmaceutical Co., Ltd

Advanced Hepatocellular Carcinoma

07/24

12/24

TACE-TKI-ICI, NCT05717738: Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

Recruiting

N/A

300

RoW

TACE, transarterial chemoembolization, Lenvatinib, levima, Anti-PD-1 monoclonal antibody, PD-1 inhibitor, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, apatinib plus camrelizumab, Apa plus C, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga

Tongji Hospital, Chinese Cooperative Group of Liver Cancer, Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, The Second Affiliated Hospital of Fujian Medical University, Geneplus-Beijing Co. Ltd., Haplox Biotechnology Co., Ltd.

Hepatocellular Carcinoma Non-resectable

12/23

12/24

CCGLC-001, NCT05713994: Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Recruiting

N/A

300

RoW

HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Lenvatinib, Lenvima, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga, apatinib plus camrelizumab, Apa plus C, Anti-PD-1 monoclonal antibody, PD-1 inhibitor

Wan-Guang Zhang, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, Haplox Biotechnology Co., Ltd., Geneplus-Beijing Co. Ltd., The Second Affiliated Hospital of Fujian Medical University

Hepatocellular Carcinoma Non-resectable

04/24

12/24

DELINOR, NCT05834348: A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

Recruiting

N/A

20605

Europe

lorlatinib, crizotinib, brigatinib, ceritinib, alectinib, atezolizumab, bevacizumab, paclitaxel, carboplatin, docetaxel, erlotinib, gefitinib, afatinib, dacomitinib, osimertinib, pembrolizumab, nivolumab, entrectinib

Pfizer

Non-Small Cell Lung Cancer

02/25

KOSMOS-II, NCT05525858: KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

Recruiting

N/A

1000

RoW

Alectinib, Alecensa, Atezolizumab, Tecentriq, Erlotinib, Tarceva, Trastuzumab + Pertuzumab, Herceptin + Perjeta, Trastuzumab emtansine, Kadcyla, Vemurafenib, Zelboraf, Bevacizumab + Erlotinib, Avastin + Tarceva, Entrectinib, Rozlytrek, Pralsetinib, Gavreto

Seoul National University Bundang Hospital, Korean Cancer Study Group, Roche Pharma AG

Solid Tumor, Advanced Solid Tumor, Metastatic Cancer

09/25

LATINA, NCT04158258: A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Active, not recruiting

N/A

2907

RoW

Bevacizumab, Avastin, Trastuzumab, Herceptin, Ado-trastuzumab emtamsine, Kadcyla, Pertuzumab, Perjeta, Atezolizumab, Tecentriq, Capecitabine

Hoffmann-La Roche, Latin American Cooperative Oncology Group

Breast Cancer

11/25

IMreal, NCT03782207: A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

Active, not recruiting

N/A

3040

Europe, RoW

Atezolizumab, Tecentriq

Hoffmann-La Roche

Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma

07/26

REFINE-IO, NCT06117891: An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery

Recruiting

N/A

300

Europe, US, RoW

Atezolizumab, Bevacizumab, Durvalumab, Tremelimumab,

Bayer

Unresectable Hepatocellular Carcinoma

11/26

02/27



	Diseases Companies Products Productz Mechanisms of Action Sites